Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 2:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 1,743 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cardiovascular Risks Clear all

Conditions: Multiple Myeloma
Interventions: Lenalidomide, Prednisone, Dexamethasone; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 65 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Atherosclerotic Cardiovascular Disease
Interventions: Inclisiran; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 23
States / cities: Birmingham, Alabama • Orange, California • San Francisco, California + 20 more

Conditions: Multiple Myeloma
Interventions: nutrition counseling and coaching, dietary guidelines, research dietitian visit, Questionnaires, Frozen pre-prepared meals; Other · Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Heart Failure, Diabetes
Interventions: Message with EchoGo, Standard Message; Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: Not listed
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: HIV, Alcohol, Smoking Cigarette, Cardiovascular Disease Prevention
Interventions: Semaglutide (Rybelsus®), Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 89 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Venous Thromboembolism, Arterial Thromboembolism
Interventions: IMPROVE DD VTE Tool; Other
Lead sponsor: Northwell Health; Other
Eligibility: 60 Years and older
Enrollment: 10,699 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 5
States / cities: Manhasset, New York • New Hyde Park, New York • New York, New York + 1 more

Conditions: Diabetes Mellitus, Non-Insulin-Dependent, Glucose Intolerance
Interventions: Intensive lifestyle, Metformin, Placebo; Behavioral · Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 25 Years and older
Enrollment: 3,234 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1996 – 2001
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Sudden Cardiac Death
Interventions: Electrophysiology study (EPS), Standard Care, Cardiac Magnetic Resonance (CMR); Procedure · Other
Lead sponsor: Western Sydney Local Health District; Other
Eligibility: 18 Years to 85 Years
Enrollment: 1,058 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obesity, Venous Thrombosis, Anticoagulants
Interventions: Enoxaparin 0.5 mg/kg once daily; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Atrial Fibrillation
Interventions: Heart healthy Engagement Program with the Apple Watch Series 5 or later, Anti-Coagulation Adherence Module with the Apple Watch Series 5 or later; Device
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 65 Years and older
Enrollment: 34,244 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: San Mateo, California

Conditions: Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure, Respiratory Complication, Respiratory Insufficiency, Cardiac Dysfunction, Pneumonia, Pulmonary Edema, Pulmonary Inflammation, Respiratory Failure, Cytokine Storm, COVID 19, SARS-CoV-2, Cardiac Event, Cardiac Complication, Cardiac Failure, Cardiac Infarct
Interventions: Pemziviptadil (PB1046), Low Dose (10 mg) Control; Drug
Lead sponsor: PhaseBio Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 4
States / cities: Jacksonville, Florida • Sarasota, Florida • Kansas City, Kansas + 1 more

Conditions: Cardiovascular Disease
Interventions: reciprocal peer support and non reciprocal coach support; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 35 Years to 64 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Metabolic Disease, Obesity, Li-Fraumeni Syndrome, Cardiomyopathy, Atherosclerosis, Inflammatory Disease
Interventions: NSR IDE-MRI: Research pulse sequences; Device
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 1 Year to 100 Years
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2010
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Hyperlipidemia
Interventions: Bococizumab (PF-04950615; RN316), Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 2,139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 155
States / cities: Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 115 more

Conditions: Cardiovascular Disease Risk Reduction
Interventions: Health for Hearts United Planning for Health, Health for Hearts United Preparing for Health, Health for Hearts United Delivery of Health, Health for Hearts United Comparison Group Health Ministry Development; Behavioral · Other
Lead sponsor: Florida State University; Other
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Heterozygous Familial Hypercholesterolemia, Non-familial Hypercholesterolemia
Interventions: Praluent; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 1,389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 57
States / cities: Auburn, Alabama • Mobile, Alabama • Beverly Hills, California + 50 more

Conditions: Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Coronary Disease
Interventions: hypoglycemic agents, hydroxymethylglutaryl-CoA Reductase inhibitors, hypertensive agents; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 40 Years to 79 Years
Enrollment: 7,287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 4
States / cities: Minneapolis, Minnesota • Winston-Salem, North Carolina • Cleveland, Ohio + 1 more

Conditions: Aortic Stenosis
Interventions: TAVR, Warfarin plus Aspirin, Aspirin Only; Device · Other
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: Not listed
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 7
States / cities: San Diego, California • Washington D.C., District of Columbia • Ridgewood, New Jersey + 4 more

Conditions: Obstetric Labor Complications, Cardiovascular Diseases in Pregnancy, Cardiovascular Risk Factor
Interventions: Not listed
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Prostate Cancer Metastatic Disease
Interventions: Hypocaloric anti-inflammatory diet; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older · Male only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Hypertension, Hyperlipidemias
Interventions: Atorvastatin, placebo; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 35 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Prostate Cancer
Interventions: Androgen deprivation therapy; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Cardiovascular, Psychological Stress
Interventions: High Antioxidant Spice Blend, Trier Psychological Stressor, Placebo antioxidant concentrate; Dietary Supplement · Behavioral · Other
Lead sponsor: Penn State University; Other
Eligibility: 30 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Heart Failure
Interventions: Cardiac Resynchronization Therapy-Defibrillator; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma

VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease

A Dietary Study for People With Multiple Myeloma

Using Ultromics EchoGo HFpEF Algorithm to Identify and Treat High Heart Failure Risk in Patients With Type 2 Diabetes

GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV

A Universal Electronic Health Record-based IMPROVE DD VTE Risk Assessment Model for the Prevention of Thromboembolism in Hospitalized Medically Ill Patients

Diabetes Prevention Program

Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias Following Acute Myocardial Infarction (PROTECT-ICD)

Study to Evaluate Weight-based Enoxaparin Dosing in Obese Medical Patients at Risk for DVT

A Study to Investigate if Early Atrial Fibrillation (AF) Diagnosis Reduces Risk of Events Like Stroke in the Real-World

Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).

Heart Health Buddies: Peer Support to Decrease CVD Risk

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events

The Health for Hearts United Collaborative

Long Term Safety Study of PRALUENT

Intensive Glycemic Control and Skeletal Health Study

Strategies to Prevent Transcatheter Heart Valve Dysfunction in Low Risk Transcatheter Aortic Valve Replacement

Transthoracic Echocardiography of Ventricular Function of Parturients in Labor

Role of Race in Nutritional Approach in Men on ADT

Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men

Prospective Study of Insulin Resistance and Cardiovascular Disease Risk During Androgen Deprivation Therapy for Prostate Cancer

Effects of Antioxidants on Cardiovascular Risk Measures (Spice Study)

RISK Stratification Using a Combination of Cardiac Troponin T and Brain Natriuretic Peptide in Patients Receiving CRT-D